TFF Pharmaceuticals, Inc.
NASDAQ:TFFP
1.63 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.734 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.502 | 0.388 | 0.111 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0.231 | -0.388 | -0.111 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.315 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 11.559 | 18.496 | 21.301 | 10.682 | 8.822 | 0.849 | 0 | 0.229 |
| General & Administrative Expenses
| 10.567 | 13.796 | 10.574 | 8.012 | 3.165 | 0 | 0.179 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 10.567 | 13.796 | 10.574 | 8.012 | 3.165 | 3.049 | 0.179 | 0.141 |
| Other Expenses
| 0 | -0.496 | -0.088 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 22.126 | 31.797 | 31.787 | 18.694 | 11.988 | 3.898 | 0.179 | 0.37 |
| Operating Income
| -22.629 | -31.797 | -31.787 | -18.694 | -11.988 | -3.898 | -0.179 | -0.37 |
| Operating Income Ratio
| -30.834 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.385 | 0.027 | 0.748 | 0.126 | 0.117 | 0.056 | -0 | 0 |
| Income Before Tax
| -21.243 | -31.77 | -31.039 | -18.567 | -11.87 | -3.842 | -0.179 | -0.37 |
| Income Before Tax Ratio
| -28.947 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0 | -0.051 | -0.126 | -0.117 | 0 | -0.053 | 0 |
| Net Income
| -21.243 | -31.77 | -30.987 | -18.441 | -11.753 | -3.842 | -0.179 | -0.37 |
| Net Income Ratio
| -28.947 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -11.85 | -26.49 | -31.21 | -22.57 | -42.55 | -5.21 | -0.01 | -0.5 |
| EPS Diluted
| -11.85 | -26.49 | -31.21 | -22.57 | -42.55 | -5.21 | -0.01 | -0.5 |
| EBITDA
| -22.126 | -31.409 | -31.675 | -18.694 | -11.988 | -3.898 | -0.179 | -0.37 |
| EBITDA Ratio
| -30.15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |